Evidence map›Paper›PMID 34484648›Full record

ArticleRare tumors2021

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.

Karlton Wong, Jomjit Chantharasamee, Scott Nelson, Mark A Eckardt, Kambiz Motamedi, Francis J Hornicek, Arun S Singh

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Karlton WongDivision of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Jomjit ChantharasameeDivision of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-1237-331X
Scott NelsonDepartment of Pathology, University of California Los Angeles, Los Angeles, CA, USA.
Mark A EckardtDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Kambiz MotamediDepartment of Radiology, University of California Los Angeles Medical Center, Los Angeles, CA, USA.
Francis J HornicekDepartment of Orthopedic Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Arun S SinghDivision of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USSiriraj Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoblastomas and aneurysmal bone cysts (ABC) are rare benign bone tumors that make up about 1%-2% of primary bone malignancies, typically occurring in young patients with a median age of 20 years, most commonly effecting the axial skeleton. ABCs may develop independently as primary lesions, or secondary to other bony lesions including osteoblastomas, chondroblastomas, and giant cell tumors. Treatment of unresectable or extensive osteoblastomas can be challenging. In 2013, the Food and Drug Administration (FDA) approved denosumab for the treatment of giant cell tumors of the bone due to its efficacy in these morbid bony lesions. Various case reports have shown that osteoblastomas can respond to denosumab. Furthermore, numerous ABC case reports have described the efficacy of denosumab in these situations. We herein describe a unique case of a young patient with an aggressive osteoblastoma and secondary ABCs who was successfully treated with denosumab.

Indexed as

aggressive bone tumoraneurysmal bone cystbenign bone tumorbone sarcomadenosumabOsteoblastomaosteosarcoma

Identifiers

PMID34484648
PMCPMC8408893
OpenAlexW3198085408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.